F Damond

Summary

Country: France

Publications

  1. ncbi Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay
    Florence Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Clin Microbiol 43:4234-6. 2005
  2. ncbi Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
    F Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 39:4264-8. 2001
  3. ncbi Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections
    Florence Damond
    Laboratoire de Virologie, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    J Clin Microbiol 40:3654-9. 2002
  4. ncbi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
  5. ncbi Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Virol 71:8893-8. 1997
  6. ncbi Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 36:2143-5. 1998
  7. ncbi Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france
    F Damond
    Laboratoire de Virologie, , Paris Cedex 18, 75877, France
    Virology 280:19-30. 2001
  8. ncbi Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification
    F Damond
    APHP, Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 48:1413-6. 2010
  9. ncbi [HIV genetic diversity and its consequences]
    B Roquebert
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 75877 Paris Cedex 18, France
    Pathol Biol (Paris) 57:142-8. 2009
  10. ncbi Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors
    F Damond
    , Paris, France
    J Clin Microbiol 43:484-7. 2005

Detail Information

Publications48

  1. ncbi Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay
    Florence Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Clin Microbiol 43:4234-6. 2005
    ..The new version performed significantly better than the original regarding the detection of subtype B, allowing the detection of 14 out of 36 plasma RNAs in the subtype B-infected patients not detected with the original version...
  2. ncbi Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
    F Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 39:4264-8. 2001
    ..Proviral load did not correlate with plasma HIV-2 RNA positivity. As HIV-2 is considered to replicate less efficiently than HIV-1, these high proviral loads might be explained by the proliferation of infected cells...
  3. ncbi Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections
    Florence Damond
    Laboratoire de Virologie, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    J Clin Microbiol 40:3654-9. 2002
    ..14 log(10), whereas it was 3.1 log(10) for the 16 patients with AIDS (P < 0.01). Proviral DNA was detectable in 18 symptom-free patients with high CD4(+)-cell counts, in whom viral RNA was undetectable...
  4. ncbi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
    ..We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation to HIV-2 integrase gene polymorphism...
  5. ncbi Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Virol 71:8893-8. 1997
    ..The study of HIV-1 group O susceptibility to antiretroviral drugs revealed that the viruses tested had specific phenotypic characteristics contrasting with the group M phenotypic expression...
  6. ncbi Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 36:2143-5. 1998
    ..LiPA is suitable for detecting mixed populations and easy to implement in clinical laboratories and might be useful for epidemiological surveys of primary HIV-1 resistance...
  7. ncbi Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france
    F Damond
    Laboratoire de Virologie, , Paris Cedex 18, 75877, France
    Virology 280:19-30. 2001
    ..This could partly explain the double HIV-1 and HIV-2 reactive profiles found in countries where HIV-2 subtype B is prevalent...
  8. ncbi Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification
    F Damond
    APHP, Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 48:1413-6. 2010
    ..The performance of the new test was significantly improved, and the majority of the underquantitation observed with the first-version test was eliminated...
  9. ncbi [HIV genetic diversity and its consequences]
    B Roquebert
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 75877 Paris Cedex 18, France
    Pathol Biol (Paris) 57:142-8. 2009
    ..A major advance from the last year is the access to antiretroviral in resources limited countries. On the other hand, the development of a vaccine is today hypothetic...
  10. ncbi Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors
    F Damond
    , Paris, France
    J Clin Microbiol 43:484-7. 2005
    ..Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1...
  11. ncbi T cell changes after combined nucleoside analogue therapy in HIV primary infection
    G Carcelain
    Laboratoire d Immunologie Cellulaire, CNRS UMR 7527, Hopital Pitie Salpetriere, Paris, France
    AIDS 13:1077-81. 1999
    ..To characterize the immune changes after treatment of acute HIV-1 infection with triple nucleoside analogue therapy...
  12. ncbi Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays
    F Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, 75018 Paris, France
    J Clin Microbiol 45:3436-8. 2007
    ..5 and with COBAS TaqMan HIV-1 assays. Mean values were 4.2 and 2.9 log(10) copies/ml, respectively, showing the lack of agreement between the two assays...
  13. ncbi Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1
    M Burgard
    Virology Laboratory, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris, France
    Clin Infect Dis 51:833-43. 2010
    ..Methods: Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007...
  14. ncbi An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study
    F Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Clin Microbiol 49:3491-7. 2011
    ..Development of a validated HIV-2 viral load assay that accurately quantifies distinct circulating strains is needed...
  15. ncbi V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant
    J C Plantier
    Laboratoire de Virologie, , , Tours, France
    J Clin Microbiol 39:3803-7. 2001
    ..Comparison of amino acid sequences and serotype reactivities demonstrated the importance of positions 309 and 314, located on either side of the tip of the V3 loop, in antibody binding...
  16. ncbi Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma
    Janak K Maniar
    Department of Infectious Diseases, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
    Int J STD AIDS 17:781-2. 2006
    ..Salvage therapy was initiated with good clinical response...
  17. ncbi Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes
    Marie Gueudin
    Laboratoire de Virologie, Equipe d accueil 2656, Centre Hospitalier Universitaire Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Acquir Immune Defic Syndr 44:500-5. 2007
    ..We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16])...
  18. ncbi Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 11:701-5. 2006
    ..This study examined whether, in the context of a first-line abacavir/lamivudine highly active antiretroviral therapy (HAART) regimen, K65R might occur as a minority population where L74V was detected at virological failure...
  19. ncbi Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test
    Francois Rouet
    Laboratoire de Virologie, Centre Muraz, BP 390 Bobo Dioulasso 01, Burkina Faso
    J Acquir Immune Defic Syndr 45:380-8. 2007
    ..Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays...
  20. ncbi Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006
    Francis Barin
    Universite Francois Rabelais, INSERM ERI 19, Centre National de Reference du VIH, CHU Bretonneau, 37044 Tours Cedex, France
    AIDS 21:2351-3. 2007
    ..1%, respectively. Most of these cases occurred in patients infected through heterosexual contact and originated from the corresponding endemic areas. Three cases of HIV-2 infections were reported in non-African men having sex with men...
  21. ncbi Differences in proviral DNA load between HIV-1- and HIV-2-infected patients
    Marie Gueudin
    Laboratoire de Virologie, CHU Charles Nicolle Rouen, France
    AIDS 22:211-5. 2008
    ....
  22. ncbi In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
    Delphine Desbois
    Laboratoire de Virologie, Service de Microbiologie, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 52:1545-8. 2008
    ..Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1...
  23. ncbi Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France
    Julia Drylewicz
    INSERM, U875 Epidemiology and Biostatistics, Bordeaux F 33076, France
    AIDS 22:457-68. 2008
    ..We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infected patients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART)...
  24. ncbi Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients
    Florence Damond
    AIDS 22:665-6. 2008
  25. ncbi Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir
    Xavier Duval
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 46:570-4. 2002
    ..03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses...
  26. ncbi Integrase polymorphism and HIV-1 group O diversity
    Marie Leoz
    AIDS 22:1239-43. 2008
  27. ncbi Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  28. ncbi Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation
    Christophe Pasquier
    Laboratoire de Virologie, laboratoire de Spermiologie et CECOS Midi Pyrénées, Toulouse University Hospital, Toulouse, France
    J Med Virol 78:877-82. 2006
    ..This first quality control highlights the need for technical improvements of the assays to detect and quantify HIV in semen fractions and for regular evaluation of their performance...
  29. ncbi No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort
    Diane Descamps
    , Paris, France
    AIDS 20:1076-9. 2006
    ..After adjusting for age and CD4 cell count, co-infection with GBV-C was not associated with clinical progression (hazard ratio 0.78; 95% CI 0.24-2.56, 16 clinical events)...
  30. ncbi HIV-2 infection and HIV-associated nephropathy
    Hassane Izzedine
    AIDS 20:949-50. 2006
  31. ncbi Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  32. ncbi Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations
    Katharina Skrabal
    INSERM U-552, Recherche Antivirale, Paris, France
    AIDS 17:809-14. 2003
    ..Differences in target cell populations, tissue distribution and replication characteristics between R5 and X4 viruses could explain the preferential suppression of X4 virus...
  33. ncbi Plasma RNA quantification and HIV-1 divergent strains
    Jean Christophe Plantier
    Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 33:1-7. 2003
    ..In conclusion, the authors showed that the LCx kit allowed quantification of the large group M diversity and group O variants...
  34. ncbi Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Marie Gueudin
    Laboratoire de Virologie, Hopital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Virol Methods 113:43-9. 2003
    ..Despite the high initial cost of acquiring the required cycling device, the per-sample cost of this real-time quantitative PCR assay for HIV-1 group O is low, making it suitable for use in endemic zones...
  35. ncbi Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort
    Sophie Matheron
    Service des Maladies Infectieuses et Tropicales A, , , France
    AIDS 17:2593-601. 2003
    ..It is recommended in case of AIDS, CDC group B symptoms or CD4 cell count < 200 x 10(6)/l...
  36. ncbi Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification
    Florence Damond
    Virology Department, , 75877 Paris 18, France
    AIDS Res Hum Retroviruses 20:666-72. 2004
    ..The single-strain lineages C to G and the 96FR12034 lineage identified here should be considered only as putative groups until related strains are identified that confirm circulation of these viruses in the human population...
  37. ncbi High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen
    Diane Descamps
    Hopital Bichat Claude Bernard, Paris, France
    J Med Virol 74:197-201. 2004
    ..In these highly thymidine analogue pretreated patients, the selection of thymidine analogue mutations was low suggesting that the pathway to resistance is very different between these two viruses...
  38. ncbi Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen
    Florence Damond
    Antivir Ther 9:635-6. 2004
  39. ncbi CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort
    Sophie Matheron
    Bichat Claude Bernard Hospital, , Paris, France
    AIDS 20:459-62. 2006
    ..Our results raise the question of the optimal regimen to recommend in HIV-2-infected patients...
  40. ncbi Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection
    Nadia Alatrakchi
    Laboratoire d'Immunologie Cellulaire, INSERM U.543, , Paris, France
    AIDS 20:29-34. 2006
    ..In addition, lymphoproliferative responses to HIV-2 were associated with lack of viral replication...
  41. ncbi Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene
    Florence Damond
    , Paris, France
    Antivir Ther 10:861-5. 2005
    ..Clinical relevance of these phenotypic susceptibility results needs to be evaluated in HIV-2 treated patients...
  42. ncbi Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues
    Laurent Fonquernie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
    Trans R Soc Trop Med Hyg 100:282-4. 2006
    ..This immunovirological discordance was due to failure of the viral load assay and infection by an unknown HIV-2 subtype. Treatment was probably suboptimal, leading to the selection of several resistance mutations and treatment failure...
  43. ncbi Quantification of proviral DNA load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
    Marie Gueudin
    , GRAM EA 2636, CHU Charles Nicolle, Rouen, France
    Methods Mol Biol 304:215-20. 2005
    ..These primers amplify both HIV-2 subtypes A and B. The relevance of the follow-up of the infected patients by the quantification of the proviral DNA HIV-2 is currently studied...
  44. ncbi Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 42:5866-70. 2004
    ..3% of group A or B samples; isolate H was not detected. This method allowed rapid and specific discrimination between HIV-2 groups A and B and could be a useful tool for molecular epidemiological studies...
  45. ncbi The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient
    Sophie Bouvresse
    AIDS 21:1492-4. 2007
  46. ncbi Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors
    Francis Barin
    Laboratoire de Virologie, EA 3250, Universite Francois Rabelais, Tours, France
    J Infect Dis 189:322-7. 2004
    ..The results of the present study suggest that the P4P assay can be used for the extensive study of both neutralizing and enhancing activity in serum samples from HIV-1-infected patients and from vaccinated individuals...
  47. ncbi Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG
    Jean-Christophe Plantier
    Laboratoire de Virologie, Equipe d'Accueil 2639, , Tours, France
    J Clin Microbiol 40:1010-22. 2002
    ..This method can be adapted to the local situation by including only probes that correspond to the prevalent strains...